Clinical trials: Dance
Osteoporosis
Study of FORTEO Use in Subjects in the Community Setting
The purpose of this study is to evaluate the long-term effectiveness, safety, and tolerability of FORTEO in a larger, more diverse "real world" population than studied in clinical trials
- Trial name
- DANCE (NCT01078805)
- Testing
- FORTEO
- Where
- United States
- Volunteers
- 4,167 people
- Sponsor
- Eli Lilly and Company
Peripheral Arterial Disease
DANCE Partner: Inflammatory Biomarker Analysis by Femoropopliteal Revascularization Method and Treatment Outcomes
This is a prospective, multi-center, observational registry to document the baseline, 24-hour and 30-day inflammatory response and procedural outcomes out to 12 month follow-up after femoropopliteal angioplasty or…
- Trial name
- NCT02469532
- Testing
- Balloon Angioplasty, Atherectomy System
- Where
- 6 sites in United States
- Volunteers
- 31 people
- Sponsor
- Mercator MedSystems, Inc.
Type 2 Diabetes Mellitus
Dose Response of Dance 501 in Subjects With Type 2 Diabetes Mellitus
This will be a randomized, open-label, active-controlled, 6-period crossover study. Target population will be subjects with Type 2 Diabetes Mellitus (T2DM)
- Trial name
- T2DM (NCT04100473)
- Testing
- Inhaled Human Insulin, Insulin Lispro (Humalog U-100)
- Where
- Germany
- Volunteers
- 24 people
- Sponsor
- Dance Biopharm Inc.
Safety and Tolerability
PK and PD Profile of Dance 501 in Healthy, Non-diabetic Subjects With Mild to Moderate Asthma or COPD
This will be a randomized, open-label, active-controlled, single dose crossover study with either three or four treatment periods.
- Trial name
- NCT03307512
- Testing
- inhaled human insulin, Insulin Lispro (Humalog U-100)
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Dance Biopharm Inc.